# A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

> **NCT03763149** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **BIOLOGICAL:** IBI188

## Key facts

- **NCT ID:** NCT03763149
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-19
- **Primary completion:** 2021-03-29
- **Final completion:** 2021-03-29
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03763149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03763149, "A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03763149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*